Affiliations 

  • 1 M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Malaysia
  • 2 Division of Biomedical Sciences, School of Pharmacy, Faculty of Sciences and Engineering, University of Nottingham Malaysia, Semenyih 43500, Malaysia
  • 3 China-ASEAN College of Marine Sciences, Xiamen University Malaysia, Sepang 43900, Malaysia
  • 4 National Cancer Council (MAKNA), Kuala Lumpur 54000, Malaysia
Int J Mol Sci, 2023 Jan 05;24(2).
PMID: 36674525 DOI: 10.3390/ijms24021012

Abstract

Cancer recurrence and drug resistance following treatment, as well as metastatic forms of cancer, are trends that are commonly encountered in cancer management. Amidst the growing popularity of personalized medicine and targeted therapy as effective cancer treatment, studies involving the use of stem cells in cancer therapy are gaining ground as promising translational treatment options that are actively pursued by researchers due to their unique tumor-homing activities and anti-cancer properties. Therefore, this review will highlight cancer interactions with commonly studied stem cell types, namely, mesenchymal stroma/stem cells (MSC), induced pluripotent stem cells (iPSC), iPSC-derived MSC (iMSC), and cancer stem cells (CSC). A particular focus will be on the effects of paracrine signaling activities and exosomal miRNA interaction released by MSC and iMSCs within the tumor microenvironment (TME) along with their therapeutic potential as anti-cancer delivery agents. Similarly, the role of exosomal miRNA released by CSCs will be further discussed in the context of its role in cancer recurrence and metastatic spread, which leads to a better understanding of how such exosomal miRNA could be used as potential forms of non-cell-based cancer therapy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.